Guangdong, Tianjin, China Tasly Pharmaceutical appeared to be the Corporate Investor, which was created in 1994. The fund was located in Asia if to be more exact in China. The main office of represented Corporate Investor is situated in the Tianjin.
The top amount of exits for fund were in 2018. Speaking about the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Tasly Pharmaceutical performs on 16 percentage points less the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from Tasly Pharmaceutical is 100-500 millions dollars.
The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Ascletis, I-Mab Biopharma, Profusa. Among the most popular fund investment industries, there are Wellness, Medical Device. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Tasly Pharmaceutical, startups are often financed by C-Bridge Capital, Tianyi Group, Shenghua Group. The meaningful sponsors for the fund in investment in the same round are C-Bridge Capital, WTT Investment, VT Ventures. In the next rounds fund is usually obtained by C-Bridge Capital, WTT Investment, Tally Capital.
Related Funds
| Fund Name | Location |
| ADV | England, London, United Kingdom |
| Bellwether | - |
| Colorics International Ltd | - |
| FoundersPad | Bend, Oregon, United States |
| Frontline BioVentures | China, Shanghai |
| Grupo Xango | Brazil, Rio de Janeiro, Rio De Janeiro |
| Guangdong Songfa Ceramics | Chaozhou, China, Guangdong Province |
| IT Farm | Chiyoda, Japan |
| McDonnell Ventures | - |
| MI3 | Canada, Montréal, Quebec |
| PhillipCapital | Central, Central Region, Singapore |
| Rowan University | Glassboro, New Jersey, United States |
| Scania Growth Capital | Södertälje, Sweden, Vasternorrlands Lan |
| Securian Ventures | Minnesota, Saint Paul, United States |
| Shenlian Touzi | - |
| Solarisbank | Berlin, Berlin, Germany |
| Swarth Group | - |
| Tokyo Commodity Exchange | - |
| Xian Aerospace Base International Incubator | China, Shaanxi, Xian Shi |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Zhangshang Tangyi | $100M | 07 Jan 2019 | Shangcheng District, Zhejiang, China | ||
Profusa | $45M | 14 Aug 2018 | San Francisco, California, United States | ||
I-Mab Biopharma | $220M | 29 Jun 2018 | Shanghai | ||
Shuwen Biotech | 11 Apr 2018 | Deqing County, Zhejiang, China | |||
I-Mab Biopharma | $150M | 23 Mar 2017 | China, Shanghai | ||
Xiaoyusan | $15M | 22 Mar 2017 | Futian District, Guangdong Province | ||
Ascletis | $100M | 03 Jan 2017 | North Carolina, United States | ||
Ascletis | $35M | 02 Sep 2015 | North Carolina, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Zhangshang Tangyi | $100M | 07 Jan 2019 | Shangcheng District, Zhejiang, China | ||
Profusa | $45M | 14 Aug 2018 | San Francisco, California, United States | ||
I-Mab Biopharma | $220M | 29 Jun 2018 | Shanghai | ||
Shuwen Biotech | 11 Apr 2018 | Deqing County, Zhejiang, China | |||
I-Mab Biopharma | $150M | 23 Mar 2017 | China, Shanghai | ||
Xiaoyusan | $15M | 22 Mar 2017 | Futian District, Guangdong Province | ||
Ascletis | $100M | 03 Jan 2017 | North Carolina, United States | ||
Ascletis | $35M | 02 Sep 2015 | North Carolina, United States |
